Novartis snaps up allergy biotech excellergy in $2b gamble on next-gen ige blockade
Novartis just wrote the biggest cheque of the year in allergy R&D: up to $2 billion for Boston-based Excellergy and its Phase I antibody Exl-111, a molecule the Swiss giant believes can outrun every anti-IgE therapy on the planet.
The science that justifies the price tag
Exl-111 is not another me-too omalizumab. It is engineered for sub-picomolar affinity and a half-life that stretches beyond 40 days, letting it hoover up circulating IgE faster and longer than any predecessor. IgE is the ignition key for asthma, chronic spontaneous urticaria, food allergy, even atopic dermatitis; knock it out early and you throttle the whole inflammatory cascade before it starts. Novartis has seen enough in 48-week primate data to bet the farm.
Terms are classic pharma risk-sharing: $750 million at close—expected H2 2026 once the FTC and EMA finish their poking—plus $1.25 billion in staggered milestones tied to Phase II proof-of-concept, first pivotal read-out and eventual approval. Cheap if Exl-111 repeats its primate performance in humans; ruinous if it doesn’t. Fiona Marshall, president of Biomedical Research, calls it “a rocket booster for our allergy franchise,” a phrase that will either haunt or immortalise her.
Why novartis couldn’t wait
The Basel group’s respiratory pipeline has been bleeding. Its oral BTK inhibitor remibrutinib missed the mark in chronic urticaria last winter, and rival Sanofi already ships high-dose omalizumab and the next-gen duo amlitelimab/itepekimab. Buying rather than building became existential. Excellergy’s single asset gives Novartis an immediate leg-up in an IgE market forecast to top $18 billion by 2032, according Evaluate’s last refresh.
But there is a wrinkle. The FDA has never green-lit an anti-IgE for food allergy that is dosed quarterly; the agency still equates frequent exposure with anaphylaxis vigilance. Novartis will have to run gigantic safety databases in peanut-allergic toddlers before it can even whisper the word “cure.” Translation: the final bill could sail past $2.5 billion once post-marketing commitments are tallied.
Still, the deal is already rippling through Boston’s biotech corridors. Venture backers ARCH and Flagship pocket a 12× return on the $170 million they pumped in since 2019, and every allergy platform with an IgE angle—from small-molecule degraders to CAR-Tregs—just got an instant valuation bump. The message is blunt: if you can crack IgE, the money firehose is waiting.
For patients the arithmetic is simpler. If Exl-111 survives Phase II, the first once-a-season shot that erases peanut terror could hit clinics in 2029. That is a big “if,” but yesterday’s announcement makes it the most expensive “if” Wall Street has financed in years. Novartis has gone all-in; now the molecule has to deliver or the house always wins.